Literature DB >> 9262363

Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.

T Ito1, I Yano, K Tanaka, K I Inui.   

Abstract

The purpose of this study was to characterize the transport mechanisms involved in the renal tubular secretion of quinolones. The contribution of P-glycoprotein to the transport of quinolones was elucidated using a kidney epithelial cell line, LLC-PK1, and its transfectant derivative cell line, LLC-GA5-COL150, which expresses human P-glycoprotein on the apical membrane. The transcellular transport of levofloxacin, a quinolone antibacterial drug, from the basolateral to apical side was increased in LLC-GA5-COL150 compared with that in LLC-PK1 monolayers. The apparent Michaelis constant and maximum velocity values for the saturable transcellular transport of levofloxacin from the basolateral to apical side in LLC-GA5-COL150 monolayers were 3.0 mM and 45 nmol/mg protein per 15 min, respectively. The increased basolateral-to-apical transport in LLC-GA5-COL150 monolayers was completely inhibited by cyclosporin A and quinidine to the level observed in LLC-PK1 monolayers. In addition, 3 mM levofloxacin inhibited the basolateral-to-apical transport of daunorubicin in LLC-GA5-COL150 monolayers. The basolateral-to-apical transport of another quinolone antibacterial drug, DU-6859a, in LLC-GA5-COL150 monolayers greatly exceeded than that in LLC-PK1 monolayers, and was inhibited by levofloxacin. These findings suggest that quinolone antibacterial drugs are transported by P-glycoprotein, and that P-glycoprotein may contribute at least in part to the renal tubular secretion of quinolones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262363

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

1.  Transepithelial transport of diphenhydramine across monolayers of the human intestinal epithelial cell line Caco-2.

Authors:  H Mizuuchi; T Katsura; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

Review 2.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

3.  Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

Authors:  J A Schrickx; J Fink-Gremmels
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Authors:  Anushka Naidoo; Veron Ramsuran; Maxwell Chirehwa; Paolo Denti; Helen McIlleron; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Ravesh Singh; Sinaye Ngcapu; Mamoonah Chaudhry; Michael S Pepper; Nesri Padayatchi
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

6.  Transport of levofloxacin in the OK kidney epithelial cell line: interaction with p-aminohippurate transport.

Authors:  Y Matsuo; I Yano; Y Habu; T Katsura; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

7.  Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.

Authors:  Kazumasa Naruhashi; Ikumi Tamai; Natsuko Inoue; Hiromi Muraoka; Yoshimichi Sai; Nagao Suzuki; Akira Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats.

Authors:  A Delon; S Bouquet; F Huguet; V Brunet; P Courtois; W Couet
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 9.  A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal:  J Clin Pharmacol       Date:  2017-07-24       Impact factor: 3.126

10.  Levofloxacin pharmacokinetics in adult cystic fibrosis.

Authors:  Carlton K K Lee; Michael P Boyle; Marie Diener-West; Lois Brass-Ernst; Michelle Noschese; Pamela L Zeitlin
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.